Published :
Tables : 54
Figures : 50
Category : Healthcare
No. of Pages : 220
Report Code : HC-1282
In Vitro Diagnostic Market is poised to register a CAGR of 4.1% during the forecast period 2022 to 2028. Technological advancements in in-vitro diagnostic techniques have contributed to the global in-vitro diagnostics market growth. With the assistance of key players in launching advanced in-vitro diagnostic tools, the market for these products will most likely see much growth. For instance, Qiagen, which is a company that ranks as one of the prominent providers of point of care molecular diagnostics, provides the highest record of accurate results for particularized patient treatments. Moreover, the government officiated the healthcare system and other organizations have had a positive effect on market growth. Owing to government programs, there has been significant education and information regarding IVD tools and personalized medication and treatment. All these factors have served as the basis for lucrative business opportunities. Thus, the exorbitant costs of in-vitro treatment may pose potential problems in the progress during the forecast time frame. The market is expected to see a boost in the demand for in-vitro diagnostic kits and reagents. Major players are looking to develop highly innovative kits for an accurate diagnosis. There is a demand for software in diagnostic devices and tools by medical professionals. Also, there has also been a need for it in terms of diagnosing various chronic diseases. By technology, the market has been divided into applications related to clinical chemistry. This clinical chemistry includes diagnosing blood glucose levels and detection of hormone fluctuations. Application-wise, alarming levels of ailments in cardiovascular diseases include stroke, arrhythmia and coronary artery disease is expected to spurn the demand for in-vitro diagnostic treatments. Based on the end-user, point of care diagnostic examinations includes pregnancy kits, glucose meters and biosensors that will deliver fast results. Observing the segmentation by region, North America and the Asia Pacific have been predicted to hold the largest global in-vitro diagnostics market share. A rise in diseases, as well as growing awareness in the public arena, has propelled much considerable growth in the region of North America. In the Asia Pacific region, shifts in healthcare reforms and healthcare expenditure is registered to boost regional business growth. While the market for in-vitro consists of many major players, there are smaller to midsize companies as well who are making their presence felt in the market by adopting technological changes and improvements in their products. These strategies are carried out by launching products at a much lower price. Some of these companies include Siemens Healthcare, Abbott Laboratories, Qiagen N.V., Thermo Fischer Scientific Inc., F. Hoffmann-La Roche AG, Roche Diagnostics, Danaher Corporation, Sysmex Corporation, Becton, Dickinson and Company, Biomérieux Sa, Bio-Rad Laboratories, Inc., Johnson & Johnson, Agilent Technologies, Qiagen, Diasorin, Leica Biosystems Nussloch GmbH, Cepheid have acquired a sizeable market share. Impact of COVID-19 on In vitro Diagnostics Market: The FDA has announced policies for developing specific laboratories that can conduct diagnostic tests for COVID-19. FDA has published some guidelines that are intended to aid the United States in increasing the capacity of rapid testing. Furthermore, the agency emphasized that they are not updating or changing their standards in order to issue an Emergency Use Authorization (EUA). Currently the in vitro diagnostic tests for diagnosing COVID-19 are based on real time RT-PCR testing. It is a nuclear-derived procedure that detects the presence of a genetic material from a virus. The method uses fluorescent dyes, replacing the isotope labelling which helps the scientists in obtaining immediate results even while the process is ongoing. Companies like Abbott Laboratories, Thermo Fisher Scientific, Quidel Corp., Roche Diagnostics and Hologic have receives EUA license from FDA for the commercialization of diagnostic assays used for COVID-19. Such factors can aid in the augmentation of the market. In vitro Diagnostics Market Segmentation: By Product and Services • Reagents & Kits • Instruments o Fully-automated Instruments o Semi-automated Instruments o Others • Data Management Software • Services • Extremities Implant By Technology • Immunochemistry/Immunoassay o Enzyme-Linked Immunosorbent Assay (ELISA) • Chemiluminescence Immunoassay (CLIA) • Fluorescence Immunoassay (FIA) • Colorimetric Immunoassay (CI) o Radioimmunoassays (RIA) o Rapid Tests o Western Blot o ELISPOT • Clinical Chemistry o Basic Metabolic Panel o Electrolyte Panel o Liver Panel o Lipid Profile o Renal Profile o Thyroid Function Panel o Specialty Chemicals • Molecular Diagnostics o Polymerase Chain Reaction (PCR) o Isothermal Nucleic Acid Amplification Technology (INAAT) o Hybridization (In-situ Hybridization & FISH) o DNA Sequencing & NGS o Microarray o Others • Microbiology • Hematology • Coagulation & Hemostasis • Urinalysis • Others By Application • Diabetes • Infectious Diseases • Oncology/Cancer • Cardiology • Nephrology • Autoimmune Diseases • Drug Testing/Pharmacogenomics • HIV/AIDS • Others By End User • Laboratories o Large/Reference Laboratories o Medium-sized Laboratories o Small Laboratories • Hospitals • Academics • Point-Of-Care Testing • Patient Self-Testing • Others By Region • North America • Europe • Asia Pacific • Latin America • Middle East & Africa FutureWise Key Takeaways: Growth prospects SWOT analysis Key trends Key data-points affecting market growth Objectives of the Study: To provide with an exhaustive analysis on the In-vitro diagnostics market by product & services, by technology, by application, by end user and by region To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints) To evaluate and forecast micro-markets and the overall market To predict the market size, in key regions (along with countries)— North America, Europe, Asia Pacific, Latin America and Middle East & Africa To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions Profiling of companies to evaluate their market shares, strategies, financials and core competencies Flexible Delivery Model: We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement The customization Mobility Care offered are free of charge with purchase of any license of the report You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com
Technological advancements in in-vitro diagnostic techniques have contributed to the global in-vitro diagnostics market growth. With the assistance of key players in launching advanced in-vitro diagnostic tools, the market for these products will most likely see much growth. For instance, Qiagen, which is a company that ranks as one of the prominent providers of point of care molecular diagnostics, provides the highest record of accurate results for particularized patient treatments.
Moreover, the government officiated the healthcare system and other organizations have had a positive effect on market growth. Owing to government programs, there has been significant education and information regarding IVD tools and personalized medication and treatment. All these factors have served as the basis for lucrative business opportunities. Thus, the exorbitant costs of in-vitro treatment may pose potential problems in the progress during the forecast time frame. The market is expected to see a boost in the demand for in-vitro diagnostic kits and reagents. Major players are looking to develop highly innovative kits for an accurate diagnosis. There is a demand for software in diagnostic devices and tools by medical professionals. Also, there has also been a need for it in terms of diagnosing various chronic diseases. By technology, the market has been divided into applications related to clinical chemistry. This clinical chemistry includes diagnosing blood glucose levels and detection of hormone fluctuations.
Application-wise, alarming levels of ailments in cardiovascular diseases include stroke, arrhythmia and coronary artery disease is expected to spurn the demand for in-vitro diagnostic treatments. Based on the end-user, point of care diagnostic examinations includes pregnancy kits, glucose meters and biosensors that will deliver fast results. Observing the segmentation by region, North America and the Asia Pacific have been predicted to hold the largest global in-vitro diagnostics market share. A rise in diseases, as well as growing awareness in the public arena, has propelled much considerable growth in the region of North America. In the Asia Pacific region, shifts in healthcare reforms and healthcare expenditure is registered to boost regional business growth. While the market for in-vitro consists of many major players, there are smaller to midsize companies as well who are making their presence felt in the market by adopting technological changes and improvements in their products. These strategies are carried out by launching products at a much lower price. Some of these companies include Siemens Healthcare, Abbott Laboratories, Qiagen N.V., Thermo Fischer Scientific Inc., F. Hoffmann-La Roche AG, Roche Diagnostics, Danaher Corporation, Sysmex Corporation, Becton, Dickinson and Company, Biomérieux Sa, Bio-Rad Laboratories, Inc., Johnson & Johnson, Agilent Technologies, Qiagen, Diasorin, Leica Biosystems Nussloch GmbH, Cepheid have acquired a sizeable market share.
Impact of COVID-19 on In vitro Diagnostics Market:
The FDA has announced policies for developing specific laboratories that can conduct diagnostic tests for COVID-19. FDA has published some guidelines that are intended to aid the United States in increasing the capacity of rapid testing. Furthermore, the agency emphasized that they are not updating or changing their standards in order to issue an Emergency Use Authorization (EUA). Currently the in vitro diagnostic tests for diagnosing COVID-19 are based on real time RT-PCR testing. It is a nuclear-derived procedure that detects the presence of a genetic material from a virus. The method uses fluorescent dyes, replacing the isotope labelling which helps the scientists in obtaining immediate results even while the process is ongoing. Companies like Abbott Laboratories, Thermo Fisher Scientific, Quidel Corp., Roche Diagnostics and Hologic have receives EUA license from FDA for the commercialization of diagnostic assays used for COVID-19. Such factors can aid in the augmentation of the market.
In vitro Diagnostics Market Segmentation:
By Product and Services • Reagents & Kits • Instruments o Fully-automated Instruments o Semi-automated Instruments o Others • Data Management Software • Services • Extremities Implant
By Technology • Immunochemistry/Immunoassay o Enzyme-Linked Immunosorbent Assay (ELISA) • Chemiluminescence Immunoassay (CLIA) • Fluorescence Immunoassay (FIA) • Colorimetric Immunoassay (CI) o Radioimmunoassays (RIA) o Rapid Tests o Western Blot o ELISPOT • Clinical Chemistry o Basic Metabolic Panel o Electrolyte Panel o Liver Panel o Lipid Profile o Renal Profile o Thyroid Function Panel o Specialty Chemicals • Molecular Diagnostics o Polymerase Chain Reaction (PCR) o Isothermal Nucleic Acid Amplification Technology (INAAT) o Hybridization (In-situ Hybridization & FISH) o DNA Sequencing & NGS o Microarray o Others • Microbiology • Hematology • Coagulation & Hemostasis • Urinalysis • Others
By Application • Diabetes • Infectious Diseases • Oncology/Cancer • Cardiology • Nephrology • Autoimmune Diseases • Drug Testing/Pharmacogenomics • HIV/AIDS • Others
By End User • Laboratories o Large/Reference Laboratories o Medium-sized Laboratories o Small Laboratories • Hospitals • Academics • Point-Of-Care Testing • Patient Self-Testing • Others
By Region • North America • Europe • Asia Pacific • Latin America • Middle East & Africa
FutureWise Key Takeaways:
Objectives of the Study:
Flexible Delivery Model:
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders 2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study 3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights 4. In Vitro Diagnostics Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances 5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of In Vitro Diagnostics Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework 6. In Vitro Diagnostics Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies 7. In Vitro Diagnostics Market, By Product and Services Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Reagents & Kits 7.2. Instruments 7.2.1. Fully-automated Instruments 7.2.2. Semi-automated Instruments 7.2.3. Others 7.3. Data Management Software 7.4. Services 7.5. Extremities Implant 8. In Vitro Diagnostics Market, By Technology Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Immunochemistry/Immunoassay 8.1.1. Enzyme-Linked Immunosorbent Assay (ELISA) 8.1.1.1. Chemiluminescence Immunoassay (CLIA) 8.1.1.2. Fluorescence Immunoassay (FIA) 8.1.1.3. Colorimetric Immunoassay (CI) 8.1.2. Radioimmunoassays (RIA) 8.1.3. Rapid Tests 8.1.4. Western Blot 8.1.5. ELISPOT 8.2. Clinical Chemistry 8.2.1. Basic Metabolic Panel 8.2.2. Electrolyte Panel 8.2.3. Liver Panel 8.2.4. Lipid Profile 8.2.5. Renal Profile 8.2.6. Thyroid Function Panel 8.2.7. Specialty Chemicals 8.3. Molecular Diagnostics 8.3.1. Polymerase Chain Reaction (PCR) 8.3.2. Isothermal Nucleic Acid Amplification Technology (INAAT) 8.3.3. Hybridization (In-situ Hybridization & FISH) 8.3.4. DNA Sequencing & NGS 8.3.5. Microarray 8.3.6. Others 8.4. Microbiology 8.5. Hematology 8.6. Coagulation & Hemostasis 8.7. Urinalysis 8.8. Others 9. In Vitro Diagnostics Market, By Application Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Diabetes 9.2. Infectious Diseases 9.3. Oncology/Cancer 9.4. Cardiology 9.5. Nephrology 9.6. Autoimmune Diseases 9.7. Drug Testing/Pharmacogenomics 9.8. HIV/AIDS 9.9. Others 10. In Vitro Diagnostics Market, By End-user Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Laboratories 10.1.1. Large/Reference Laboratories 10.1.2. Medium-sized Laboratories 10.1.3. Small Laboratories 10.2. Hospitals 10.3. Academics 10.4. Point-Of-Care Testing 10.5. Patient Self-Testing 10.6. Others 11. North America In Vitro Diagnostics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2022-2028 12. Latin America In Vitro Diagnostics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Brazil 12.2.2. Venezuela 12.2.3. Argentina 12.2.4. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2022-2028 13. Europe In Vitro Diagnostics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2022-2028 14. Asia Pacific In Vitro Diagnostics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028 15. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. GCC 15.2.2. Israel 15.2.3. South Africa 15.2.4. Rest of MEA 15.3. Market Size (USD Million) Forecast for MEA 2022-2028 16. Market Share Analysis and Competitive Landscape 16.1. Global Landscape - Key Players, Revenue and Presence 16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 16.3. Global Emerging Companies 16.4. North America - Market Share Analysis and Key Regional Players 16.5. Europe - Market Share Analysis and Key Regional Players 16.6. Asia Pacific - Market Share Analysis and Key Regional Players 16.7. Global Key Player - Growth Matrix 17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 17.1. Roche Diagnostics 17.1.1. Company Overview 17.1.2. Product Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. Danaher Corporation 17.2.1. Company Overview 17.2.2. Product Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3. Abbott Laboratories, Inc. 17.3.1. Company Overview 17.3.2. Product Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. Siemens AG 17.4.1. Company Overview 17.4.2. Product Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5. Sysmex Corporation 17.5.1. Company Overview 17.5.2. Product Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6. Thermo Fisher Scientific 17.6.1. Company Overview 17.6.2. Product Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. Becton, Dickinson and Company 17.7.1. Company Overview 17.7.2. Product Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Biomérieux Sa 17.8.1. Company Overview 17.8.2. Product Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. Bio-Rad Laboratories, Inc. 17.9.1. Company Overview 17.9.2. Product Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10.Johnson & Johnson 17.10.1. Company Overview 17.10.2. Product Portfolio 17.10.3. SWOT Analysis 17.10.4. Financial Overview 17.10.5. Strategic Overview 17.11.Agilent Technologies 17.11.1. Company Overview 17.11.2. Product Portfolio 17.11.3. SWOT Analysis 17.11.4. Financial Overview 17.11.5. Strategic Overview 17.12.Qiagen 17.12.1. Company Overview 17.12.2. Product Portfolio 17.12.3. SWOT Analysis 17.12.4. Financial Overview 17.12.5. Strategic Overview 17.13.Diasorin 17.13.1. Company Overview 17.13.2. Product Portfolio 17.13.3. SWOT Analysis 17.13.4. Financial Overview 17.13.5. Strategic Overview 17.14.Leica Biosystems Nussloch GmbH 17.14.1. Company Overview 17.14.2. Product Portfolio 17.14.3. SWOT Analysis 17.14.4. Financial Overview 17.14.5. Strategic Overview 17.15.Cepheid 17.15.1. Company Overview 17.15.2. Product Portfolio 17.15.3. SWOT Analysis 17.15.4. Financial Overview 17.15.5. Strategic Overview 18. Pre and Post COVID-19 Impact 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations 19. FutureWise SME Key Takeaway Points for Client
1. Market Introduction 1.1. Objectives of the Study 1.2. Market Definition 1.3. Market Scope 1.3.1. Years Considered for the Study 1.3.2. Market Covered 1.4. Currency 1.5. Limitations 1.6. Stakeholders
2. Research Methodology 2.1. Research Data 2.1.1. Secondary Data 2.1.1.1. Key Data from Secondary Sources 2.1.2. Primary Data 2.1.2.1. Key Data from Primary Sources 2.2. Market Size Estimation 2.3. Market Breakdown and Data Triangulation 2.4. Assumptions for the Study
3. Executive Summary 3.1. Market Outlook 3.2. Segment Outlook 3.3. Competitive Insights
4. In Vitro Diagnostics Market Variables, Trends & Scope 4.1. Market Lineage Outlook 4.2. Penetration and Growth Prospect Mapping 4.3. Industry Value Chain Analysis 4.4. Cost Analysis Breakdown 4.5. Technology Overview 4.6. Regulatory Framework 4.6.1. Reimbursement Framework 4.6.2. Standards and Compliances
5. Market Overview 5.1. Market Dynamics 5.1.1. Market Driver Analysis 5.1.1.1. Increasing focus of In Vitro Diagnostics Market Companies on Brand Protection 5.1.1.2. Untapped Opportunities in Emerging Regions 5.1.2. Market Restraint Analysis 5.1.2.1. High Cost Associated with Implementation of Predictive Analysis 5.1.3. Industry Challenges 5.1.3.1. Presence of Ambiguous Regulatory Framework
6. In Vitro Diagnostics Market Analysis Tools 6.1. Industry Analysis - Porter’s 6.1.1. Supplier Power 6.1.2. Buyer Power 6.1.3. Substitution Threat 6.1.4. Threat from New Entrants 6.1.5. Competitive Rivalry 6.2. Pestel Analysis 6.2.1. Political Landscape 6.2.2. Environmental Landscape 6.2.3. Social Landscape 6.2.4. Technology Landscape 6.2.5. Legal Landscape 6.3. Major Deals And Strategic Alliances Analysis 6.3.1. Joint Ventures 6.3.2. Mergers and Acquisitions 6.3.3. Licensing and Partnership 6.3.4. Technology Collaborations 6.3.5. Strategic Divestments 6.4. Market Entry Strategies 6.5. Case Studies
7. In Vitro Diagnostics Market, By Product and Services Historical Analysis and Forecast 2022-2028 (USD Million) 7.1. Reagents & Kits 7.2. Instruments 7.2.1. Fully-automated Instruments 7.2.2. Semi-automated Instruments 7.2.3. Others 7.3. Data Management Software 7.4. Services 7.5. Extremities Implant
8. In Vitro Diagnostics Market, By Technology Historical Analysis and Forecast 2022-2028 (USD Million) 8.1. Immunochemistry/Immunoassay 8.1.1. Enzyme-Linked Immunosorbent Assay (ELISA) 8.1.1.1. Chemiluminescence Immunoassay (CLIA) 8.1.1.2. Fluorescence Immunoassay (FIA) 8.1.1.3. Colorimetric Immunoassay (CI) 8.1.2. Radioimmunoassays (RIA) 8.1.3. Rapid Tests 8.1.4. Western Blot 8.1.5. ELISPOT 8.2. Clinical Chemistry 8.2.1. Basic Metabolic Panel 8.2.2. Electrolyte Panel 8.2.3. Liver Panel 8.2.4. Lipid Profile 8.2.5. Renal Profile 8.2.6. Thyroid Function Panel 8.2.7. Specialty Chemicals 8.3. Molecular Diagnostics 8.3.1. Polymerase Chain Reaction (PCR) 8.3.2. Isothermal Nucleic Acid Amplification Technology (INAAT) 8.3.3. Hybridization (In-situ Hybridization & FISH) 8.3.4. DNA Sequencing & NGS 8.3.5. Microarray 8.3.6. Others 8.4. Microbiology 8.5. Hematology 8.6. Coagulation & Hemostasis 8.7. Urinalysis 8.8. Others
9. In Vitro Diagnostics Market, By Application Historical Analysis and Forecast 2022-2028 (USD Million) 9.1. Diabetes 9.2. Infectious Diseases 9.3. Oncology/Cancer 9.4. Cardiology 9.5. Nephrology 9.6. Autoimmune Diseases 9.7. Drug Testing/Pharmacogenomics 9.8. HIV/AIDS 9.9. Others
10. In Vitro Diagnostics Market, By End-user Historical Analysis and Forecast 2022-2028 (USD Million) 10.1. Laboratories 10.1.1. Large/Reference Laboratories 10.1.2. Medium-sized Laboratories 10.1.3. Small Laboratories 10.2. Hospitals 10.3. Academics 10.4. Point-Of-Care Testing 10.5. Patient Self-Testing 10.6. Others
11. North America In Vitro Diagnostics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 11.1. Introduction 11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 11.2.1. U.S.A 11.2.2. Canada 11.2.3. Mexico 11.3. Market Size (USD Million) Forecast for North America 2022-2028
12. Latin America In Vitro Diagnostics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 12.1. Introduction 12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 12.2.1. Brazil 12.2.2. Venezuela 12.2.3. Argentina 12.2.4. Rest of Latin America 12.3. Market Size (USD Million) Forecast for Latin America 2022-2028
13. Europe In Vitro Diagnostics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 13.1. Introduction 13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 13.2.1. Germany 13.2.2. U.K 13.2.3. France 13.2.4. Italy 13.2.5. Spain 13.2.6. Russia 13.2.7. Poland 13.2.8. Rest of Europe 13.3. Market Size (USD Million) Forecast for Europe 2022-2028
14. Asia Pacific In Vitro Diagnostics Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 14.1. Introduction 14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 14.2.1. Japan 14.2.2. China 14.2.3. India 14.2.4. Australia and New Zealand 14.2.5. ASEAN 14.2.6. Rest of Asia Pacific 14.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028
15. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million) 15.1. Introduction 15.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020 15.2.1. GCC 15.2.2. Israel 15.2.3. South Africa 15.2.4. Rest of MEA 15.3. Market Size (USD Million) Forecast for MEA 2022-2028
16. Market Share Analysis and Competitive Landscape 16.1. Global Landscape - Key Players, Revenue and Presence 16.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3) 16.3. Global Emerging Companies 16.4. North America - Market Share Analysis and Key Regional Players 16.5. Europe - Market Share Analysis and Key Regional Players 16.6. Asia Pacific - Market Share Analysis and Key Regional Players 16.7. Global Key Player - Growth Matrix
17. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts) 17.1. Roche Diagnostics 17.1.1. Company Overview 17.1.2. Product Portfolio 17.1.3. SWOT Analysis 17.1.4. Financial Overview 17.1.5. Strategic Overview 17.2. Danaher Corporation 17.2.1. Company Overview 17.2.2. Product Portfolio 17.2.3. SWOT Analysis 17.2.4. Financial Overview 17.2.5. Strategic Overview 17.3. Abbott Laboratories, Inc. 17.3.1. Company Overview 17.3.2. Product Portfolio 17.3.3. SWOT Analysis 17.3.4. Financial Overview 17.3.5. Strategic Overview 17.4. Siemens AG 17.4.1. Company Overview 17.4.2. Product Portfolio 17.4.3. SWOT Analysis 17.4.4. Financial Overview 17.4.5. Strategic Overview 17.5. Sysmex Corporation 17.5.1. Company Overview 17.5.2. Product Portfolio 17.5.3. SWOT Analysis 17.5.4. Financial Overview 17.5.5. Strategic Overview 17.6. Thermo Fisher Scientific 17.6.1. Company Overview 17.6.2. Product Portfolio 17.6.3. SWOT Analysis 17.6.4. Financial Overview 17.6.5. Strategic Overview 17.7. Becton, Dickinson and Company 17.7.1. Company Overview 17.7.2. Product Portfolio 17.7.3. SWOT Analysis 17.7.4. Financial Overview 17.7.5. Strategic Overview 17.8. Biomérieux Sa 17.8.1. Company Overview 17.8.2. Product Portfolio 17.8.3. SWOT Analysis 17.8.4. Financial Overview 17.8.5. Strategic Overview 17.9. Bio-Rad Laboratories, Inc. 17.9.1. Company Overview 17.9.2. Product Portfolio 17.9.3. SWOT Analysis 17.9.4. Financial Overview 17.9.5. Strategic Overview 17.10.Johnson & Johnson 17.10.1. Company Overview 17.10.2. Product Portfolio 17.10.3. SWOT Analysis 17.10.4. Financial Overview 17.10.5. Strategic Overview 17.11.Agilent Technologies 17.11.1. Company Overview 17.11.2. Product Portfolio 17.11.3. SWOT Analysis 17.11.4. Financial Overview 17.11.5. Strategic Overview 17.12.Qiagen 17.12.1. Company Overview 17.12.2. Product Portfolio 17.12.3. SWOT Analysis 17.12.4. Financial Overview 17.12.5. Strategic Overview 17.13.Diasorin 17.13.1. Company Overview 17.13.2. Product Portfolio 17.13.3. SWOT Analysis 17.13.4. Financial Overview 17.13.5. Strategic Overview 17.14.Leica Biosystems Nussloch GmbH 17.14.1. Company Overview 17.14.2. Product Portfolio 17.14.3. SWOT Analysis 17.14.4. Financial Overview 17.14.5. Strategic Overview 17.15.Cepheid 17.15.1. Company Overview 17.15.2. Product Portfolio 17.15.3. SWOT Analysis 17.15.4. Financial Overview 17.15.5. Strategic Overview
18. Pre and Post COVID-19 Impact 18.1. Positive influence on the healthcare industry 18.2. The financial disruption of the manufacturing sector 18.3. Impact of COVID-19 on emerging companies 18.4. Significant mandates in the healthcare regulations initiated by administrations 18.5. The overall economic slowdown of the developing and developed nations
19. FutureWise SME Key Takeaway Points for Client
UK : +44 141 628 9353 US : +1 347 709 4931
OR
Excel Dataset
Infographics
PDF Report
Market Overview
PowerPoint Presentation
Consumer Perception and Procurement
Competitive Analysis
What’s Next
Market Data Forecast
Risks and Opportunity Assessment
Market Trends and Dynamics